Dr. Eric J. Small

Dr. Eric J. Small, MD, is a highly esteemed medical oncologist and urologic cancer specialist serving as Chief Scientific Officer at the UCSF Helen Diller Family Comprehensive Cancer Center. He holds multiple leadership roles, including Professor of Medicine and Urology at UCSF, Deputy Director of the Cancer Center, and Chief of the Division of Hematology and Oncology. Dr. Small earned his medical degree from Case Western Reserve University School of Medicine and completed his residency and fellowship training at UCSF, where he remains a central figure in advancing cancer research and clinical care. Board-certified in internal medicine and medical oncology, he specializes in treating prostate, kidney, and bladder cancers, offering expert, evidence-based care informed by the latest clinical trials.

Dr. Small is internationally recognized for his pioneering research in prostate cancer, particularly in the development of novel androgen receptor-targeted therapies and immunotherapies. His work has helped shape current standards for the management of advanced prostate cancer, and he has served as principal investigator on numerous national and international clinical trials. He has published extensively in top-tier journals such as The New England Journal of Medicine, Journal of Clinical Oncology, and Cancer Cell, with over 300 scientific publications to his name. His research has been instrumental in expanding treatment options for patients with metastatic and castration-resistant prostate cancer.

A passionate educator and scientific leader, Dr. Small mentors fellows and junior faculty while serving on advisory boards and steering committees for major oncology organizations. He plays a key role in shaping national research agendas through his involvement with cooperative groups such as SWOG and the Prostate Cancer Clinical Trials Consortium. Through his leadership in translational research, precision oncology, and collaborative innovation, Dr. Small continues to drive advancements that improve survival and quality of life for patients with urologic cancers.